Effect of Phosphodiester and Phosphorothioate ODNs on BV173
| ODN . | 3′ End . | Cell Counts After 72 Hours . | ||
|---|---|---|---|---|
| . | . | (% of Control ± SD) . | ||
| . | . | 2.5% NHS . | 2.5% NHSΔ . | 10% FCS . |
| PO1 | TAT | 35 ± 8 | 105 ± 7 | 114 ± 12 |
| PO2 | TCT | 81 ± 5 | ||
| PO3 | TGT | 18 ± 5 | ||
| PO4 | TTT | 25 ± 2 | ||
| PO5 | TAA | 37 ± 3 | ||
| PO6 | CAT | 53 ± 5 | ||
| PO7 | GAT | 27 ± 10 | ||
| PO8 | TAC | 118 ± 13 | ||
| PO9 | TAG | 22 ± 8 | ||
| PO10 | TGA | 22 ± 6 | 97 ± 9 | |
| PO11 | TGC | 105 ± 7 | 92 ± 11 | |
| PO12 | TTC | 119 ± 13 | 101 ± 11 | 104 ± 4 |
| PO13 | TTT | 2 ± 2 | ||
| PO14 | CCC | 123 ± 1 | ||
| PO/PS1 | TTA(pS)T | 91 ± 14 | ||
| PO/PS2 | TT(pS)AT | 36 ± 6 | ||
| PO/PS3 | T(pS)TAT | 29 ± 4 | ||
| ODN . | 3′ End . | Cell Counts After 72 Hours . | ||
|---|---|---|---|---|
| . | . | (% of Control ± SD) . | ||
| . | . | 2.5% NHS . | 2.5% NHSΔ . | 10% FCS . |
| PO1 | TAT | 35 ± 8 | 105 ± 7 | 114 ± 12 |
| PO2 | TCT | 81 ± 5 | ||
| PO3 | TGT | 18 ± 5 | ||
| PO4 | TTT | 25 ± 2 | ||
| PO5 | TAA | 37 ± 3 | ||
| PO6 | CAT | 53 ± 5 | ||
| PO7 | GAT | 27 ± 10 | ||
| PO8 | TAC | 118 ± 13 | ||
| PO9 | TAG | 22 ± 8 | ||
| PO10 | TGA | 22 ± 6 | 97 ± 9 | |
| PO11 | TGC | 105 ± 7 | 92 ± 11 | |
| PO12 | TTC | 119 ± 13 | 101 ± 11 | 104 ± 4 |
| PO13 | TTT | 2 ± 2 | ||
| PO14 | CCC | 123 ± 1 | ||
| PO/PS1 | TTA(pS)T | 91 ± 14 | ||
| PO/PS2 | TT(pS)AT | 36 ± 6 | ||
| PO/PS3 | T(pS)TAT | 29 ± 4 | ||
BV173 cell viability expressed as a percentage of control cell counts 72 hours after a single addition of phosphodiester or chimeric ODN, at a concentration of 25 μmol/L, in RPMI 1640 containing 2.5% NHS, 2.5% NHS heat-treated at 60°C for 30 minutes (NHSΔ), or 10% FCS. Data are expressed as the mean of at least three experiments ± SD.